PhoenixBio Co., Ltd. (6190.T)
JPY 335.0
(-1.76%)
JPY 335.0
(-1.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 87.93 Million JPY | -85.46% |
| 2022 | 537.41 Million JPY | 1358.12% |
| 2021 | -305.81 Million JPY | 76.45% |
| 2020 | -167.26 Million JPY | -188.32% |
| 2019 | -330.96 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 12.25 Million JPY | -32.42% |
| 2023 Q2 | -1.2 Million JPY | -102.5% |
| 2023 Q4 | 19.36 Million JPY | 246.48% |
| 2023 Q3 | -13.22 Million JPY | -1001.92% |
| 2023 FY | - JPY | -85.46% |
| 2023 Q1 | 48.04 Million JPY | -26.36% |
| 2022 Q2 | 283.84 Million JPY | 0.0% |
| 2022 FY | - JPY | 1358.12% |
| 2022 Q4 | 65.23 Million JPY | -37.08% |
| 2022 Q3 | 103.68 Million JPY | -63.47% |
| 2021 FY | - JPY | 76.45% |
| 2020 FY | - JPY | -188.32% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 90.822% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 118.015% |
| GNI Group Ltd. | 14.48 Billion JPY | 99.393% |
| Linical Co., Ltd. | 1.24 Billion JPY | 92.949% |
| Trans Genic Inc. | 240.95 Million JPY | 63.504% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 106.486% |
| Soiken Holdings Inc. | -583.2 Million JPY | 115.078% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 114.581% |
| AnGes, Inc. | -8.86 Billion JPY | 100.993% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 106.841% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 101.189% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 31.356% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 110.19% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 108.055% |
| CanBas Co., Ltd. | 53.65 Million JPY | -63.907% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 111.338% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 178.656% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 107.257% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 106.369% |
| PeptiDream Inc. | 7.37 Billion JPY | 98.808% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 104.557% |
| Ribomic Inc. | -1.01 Billion JPY | 108.685% |
| SanBio Company Limited | -4.52 Billion JPY | 101.943% |
| Healios K.K. | -3 Billion JPY | 102.924% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 107.543% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 106.313% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 106.272% |
| StemRIM | -2.03 Billion JPY | 104.328% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 93.269% |
| FunPep Company Limited | -952 Million JPY | 109.237% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 109.894% |
| Stella Pharma Corporation | -723.85 Million JPY | 112.149% |
| TMS Co., Ltd. | -937 Million JPY | 109.385% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 111.341% |
| Cuorips Inc. | -518 Million JPY | 116.976% |
| K Pharma,Inc. | 366.05 Million JPY | 75.977% |
| Takara Bio Inc. | 8.02 Billion JPY | 98.904% |
| ReproCELL Incorporated | 8.24 Million JPY | -966.562% |
| StemCell Institute Inc. | 534.35 Million JPY | 83.543% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 64.08% |
| CellSeed Inc. | -836.51 Million JPY | 110.512% |